Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 3 , Pages 252-261 , September 2008

Development, characterization, and toxicity evaluation of amphotericin B–loaded gelatin nanoparticles

Received 11 December 2007 ,Revised 13 March 2008 ,Accepted 24 March 2008.

References 

  1. Gallis HA, Drew RH, Picard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308–329
  2. Kleinberg M. What is the current and future status of conventional amphotericin B?. Int J Antimicrob Agents. 2006;27S:S12–S16
  3. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal Amphotericin B): a comparative review. J Clin Pharmacol. 1998;38:583–592
  4. Lincopan N, Mamizuka E, Carmona-Ribeiro A. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments. J Antimicrob Chemother. 2005;55:727–734
  5. Vieira DB, Carmona-Ribeiro AM. Synthetic bilayer fragments for solubilization of amphotericin B. J Colloid Interface Sci. 2001;244:427–431
  6. Nahar M, Dutta T, Murugesan S, Asthana A, Mishra D, Rajkumar V, et al. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit Rev Ther Drug Carrier Syst. 2006;23:259–318
  7. Venier-Julienne M, Benoit J. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm Acta Helv. 1996;71:121–128
  8. Espuelas MS, Legrand P, Campanero M, Appel M, Cheron M, Gamazo C, et al. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother. 2003;52:419–427
  9. Espuelas MS, Legrand P, Irache JM, Gamazo C, Orecchioni AM, Devissaguet JPh, et al. Poly (e-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharm. 1997;158:19–27
  10. Tiyabbonchai W, Limpeanchob N. Formulation and characterization of Amphotericin B–chitosan–dextran sulfate nanoparticles. Int J Pharm. 2007;329:142–149
  11. Lee CH, Singla A, Lee Y. Biomedical applications of collagen. Int J Pharm. 2001;221:1–22
  12. Narayami R, Panduranga RK. Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres. J Microencapsul. 1994;11:69–77
  13. Cascone MG, Lazzeri L, Carmignani C, Zhu Z. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med. 2002;13:523–526
  14. Leo E, Vandelli MA, Cameroni R, Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process. Int J Pharm. 1997;12:75–82
  15. Verma AK, Sachin K, Saxena A, Bohidar HB. Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor–Cycloheximide, for possible therapeutic applications. Curr Pharm Biotechnol. 2005;6:121–130
  16. Yeh TK, Lu Z, Wientjes MG, Au JLS. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res. 2005;22:867–874
  17. Bajpai AK, Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J Mater Sci Mater Med. 2006;17:345–358
  18. Sham JO, Zhang Y, Finlay WH, Roa WH, Lobenberg R. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm. 2004;28:457–467
  19. Truong-Le VL, Walsh SM, Schweibert E, Mao HQ, Guggino WB, August JT, et al. Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys. 1999;361:47–56
  20. Kaul G, Amiji M. Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)–modified gelatin nanoparticles. J Pharm Sci. 2005;94:184–198
  21. Kaul G, Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)–modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res. 2005;22:951–961
  22. Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter J, Langer K. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials. 2005;26:2723–2732
  23. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials. 2005;26:5898–5906
  24. Li JK, Wang N, Wu XS. Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method. J Microencapsul. 1998;15:163–172
  25. Coester CJ, Langer K, Van Briesen H, Kreuter J. Gelatin nanoparticles by two-step desolvation—a new preparation method, surface modifications and cell uptake. J Microencapsul. 2000;17:187–193
  26. Leo E, Cameroni R, Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticles conjugates. Int J Pharm. 1999;180:23–30
  27. Echevarrya I, Barturen C, Renedo MJ, Dios-Vieitez MC. High-performance liquid chromatographic determination of amphotericin B in plasma and tissue application to pharmacokinetic and tissue distribution studies in rats. J Chromatogr A. 1998;819:171–176
  28. Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of ketoprofen. Die Pharmazie. 1997;52:149–154
  29. Marcondes MC, Borelli P, Yoshida N, Russo M. Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment. Microbes Infect. 2000;2:347–352
  30. Azarmi S, Huang Y, Chen H, McQuarrie S, Abrams D, Roa W, et al. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharmaceut Sci. 2006;9:124–132
  31. Mazerski J, Gryzbowska J, Borowski E. Influence of net charge on the aggregation and solubility on aggregation and solubility behaviour of amphotericin B and its derivatives in aqueous media. Eur Biophys J. 1990;18:1–6
  32. Legrand P, Romero EA, Cohen BE, Bolard J. Effect of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother. 1992;36:2518–2522
  33. Saxena A, Sachin K, Bohidar HB, Verma AK. Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nano-particles. Coll Surf B: Biointerfaces. 2005;45:42–48
  34. Vandervoort J, Ludwig A. Preparation and evaluation of drug loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm. 2004;57:251–261

 The authors are thankful to the Indian Council of Medical Research, New Delhi for financial support.

PII: S1549-9634(08)00041-5

doi: 10.1016/j.nano.2008.03.007

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 3 , Pages 252-261 , September 2008

Article Tools

* Image Usage & Resolution